Courier Over $2 billion! Roche has once again partnered with Jnana to develop small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases

According to the terms of the agreement, Jnana Therapeutics will conduct drug discovery and preclinical activities
targeting multiple cancer, immune-mediated, and neurological disease targets.
The company will leverage its RAPID chemical proteomics platform to discover novel small molecule drugs targeting multiple target classes in cancer, immune-mediated and neurological diseases, and Roche will be responsible for the development and commercialization
of any related products discovered.
It is worth mentioning that today, Jnana Therapeutics also announced the completion of its $107 million Series C round, which was raised by Bain Capital Life Sciences Sciences) led the investment
.

Joel C.
Jnana Therapeutics Co-Founder, President and Chief Strategy Officer (CSO) Dr.
Barrish said, "Our existing collaboration with Roche, which focuses on targeting SLC metabolite transporters, has made exciting progress
in our internal pipeline for a range of target classes, including transcription factors.
We are excited to now bring the full power of our RAPID platform to our second partnership with Roche
.
" ”

“Jnana We were impressed by Therapeutics' team and their RAPID drug discovery platform as part of our first collaboration, focused on SLC metabolite transporters," said James Global Head of Pharma Partners at Roche Dr Sabry said, "We are now delighted with our partnership with Jnana Therapeutics builds on its successful existing collaborations to find new therapeutic targets in expanding efforts to discover new drugs for cancer, immune and neurological diseases
.
”

Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemical proteomics RAPID platform to discover drugs targeting highly validated, challenging drug targets to treat highly unmet disease
.
The company focuses on developing potential "first-in-class" and potential "best-in-class" therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancers
.
Jnana Therapeutics' lead candidate JNT-517 is a potential "first-in-class" oral approach that targets allosteric sites on the phenylalanine transporter SLC6A19 for the treatment of phenylketonuria (PKU), a rare inherited metabolic disorder
.